Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: A prospective follow-up study

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 579-584

  Sieswerda, Elske ^a   Kremer, Leontien C M ^a   Vidmar, Suzanna ^b   De Bruin, Marie L ^c   Smibert, Elizabeth ^d   Sjöberg, Gunnar ^d   Cheung, Michael M H ^d   G weintraub, Robert ^d  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UTRECHT UNIVERSITY   (Netherlands)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Anthracyclines; Cardiotoxicity; Childhood cancer survivors; Exercise echocardiography; Late effects

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN;

ABNORMAL SEPTAL MOTION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AORTIC ROOT DILATION; AORTIC SINUS DILATION; ARTICLE; BICUSPID AORTIC VALVE; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; COMPARATIVE STUDY; ECHOCARDIOGRAPHY; EWING SARCOMA; EXERCISE; EXERCISE ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE LEAFLET THICKENING; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PATIENT MONITORING; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTING ECHOCARDIOGRAPHY; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; INFANT; MALE; NEOPLASMS; ROC CURVE; SURVIVORS;

EID: 77649131927     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22371     Document Type: Article

References (41)

1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582.
2. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007;297:2705-2715.
3. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
4. Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycininduced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977;62:200-208.
5. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
6. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy:Aseries of 15 patients. Med Pediatr Oncol 1995;24:352-361.
7. Nysom K, Colan SD, Lipshultz SE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Progress Pediatr Cardiol 1998;8:121-138.
8. van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 2006;42:3191-3198.
9. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 2002;13:819-829.
10. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-2636.
11. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 2003;97:1991-1998.
12. Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003;21:2349-2356.
13. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820-828.
14. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517-4522.
15. van Dalen EC, van der Pal HJ, van den Bos C, et al. Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: The need for evidence. J Clin Oncol 2003;21:3377, author reply 3377-3378.
16. Scottish Intercollegiate Guidelines Network (SIGN). Long-term follow up care of survivors of childhood cancer. 2004: Guideline no. 76: Available at: www.sign.ac.uk/pdf/sign76.pdf.
17. Skinner R, Wallace WH, Levitt G, et al., Therapy based long term follow up: A practice statement (second edition). United Kingdom Children's Cancer Study Group, Late Effects Group. 2005: Available at: www.ukccsg.org.
18. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, version 3.0. Arcadia, CA. October 2006: Available at: www. survivorshipguidelines.org.
19. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the cardiovascular disease task force of the children's oncology group. Pediatrics 2008;121:e387-e396.
20. Landier W, Wallace WH, Hudson MM. Long-term follow-up of pediatric cancer survivors: Education, surveillance, and screening. Pediatr Blood Cancer 2006;46:149-158.
21. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The children's oncology group long-term follow-up guidelines from the children's oncology group late effects committee and nursing discipline. J Clin Oncol 2004;22:4979-4990.
22. Yeung ST, Yoong C, Spink J, et al. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991;337:816-818.
23. Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991;68:435-438.
24. Lang D, Hilger F, Binswanger J, et al. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur J Pediatr 1995;154:340-345.
25. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr 2001;160:607-610.
26. De Souza AM, Potts JE, Potts MT, et al. A stress echocardiography study of cardiac function during progressive exercise in pediatric oncology patients treated with anthracyclines. Pediatr Blood Cancer 2007;49:56-64.
27. Jarfelt M, Kujacic V, Holmgren D, et al. Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007;49:835-840.
28. Guimaraes-Filho F, Tan D, Braga J, et al. Ventricular systolic reserve in asymptomatic children previously treated with lowdoses of anthracyclines. Am J Cardiol 2007;100:1303-1306.
29. Smibert E, Carlin JB, Vidmar S, et al. Exercise echocardiography reflects cumulative anthracycline exposure during childhood. Pediatr Blood Cancer 2004;42:556-562.
30. Sahn DJ, Demaria A, Kisslo J, et al. Recommendations regarding quantitation in m-mode echocardiography - Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
31. Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol 2005;99:445-457.
32. Colan SD, Parness IA, Spevak PJ, et al. Developmental modulation of myocardial mechanics: Age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 1992;19:619-629.
33. Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: A sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992;19:394-401.
34. DeWolf D, Suys B, Verhaaren H, et al. Low-dose dobutamine stress echocardiography in children and young adults. Am J Cardiol 1998;81:895-901.
35. Cottin Y, L'Huillier I, Casasnovas O, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr 2000;1:180-183.
36. Lanzarini L, Bossi G, Laudisa ML, et al. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J 2000;140:315-323.
37. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85.
38. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635-3643.
39. Colan SD. Assessment of ventricular and myocardial performance. In: Fyler DC, editor. Nadas' pediatric cardiology. Philadelphia: Hanley and Belfus; 1992. pp 225-248.
40. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-982.
41. Devereux RB, Roman MJ, Palmieri V, et al. Prognostic implications of ejection fraction from linear echocardiographic dimensions: The strong heart study. Am Heart J 2003;146:527-534